Market Cap 43.30M
Revenue (ttm) 0.00
Net Income (ttm) -20.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.07
Volume 246,300
Avg Vol 274,798
Day's Range N/A - N/A
Shares Out 30.07M
Stochastic %K 6%
Beta 0.11
Analysts Strong Sell
Price Target $8.00

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 500 1556
Address:
4800 Montgomery Lane, Suite 220, Bethesda, United States
microcapspeculator
microcapspeculator Aug. 3 at 12:43 AM
$GANX Good article. GCase is key. Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysis https://www.nature.com/articles/s41531-025-01060-6 Our PCA-based classification provides a scalable and biologically informed tool for prognostic assessment and future stratification of PD patients with heterozygous GBA1 variants, particularly in the context of clinical trials evaluating targeted therapies, such as chaperone molecules aimed at stabilizing GCase.
1 · Reply
Trade82
Trade82 Aug. 2 at 11:58 PM
$GANX last year 2nd quarter earnings and update was 8/8/24. Hopefully some more updates from company as early as this week.
1 · Reply
Jwa68
Jwa68 Aug. 2 at 5:39 PM
$GANX A little common sense can go a long way. What's the old saying. "right under your nose".
1 · Reply
microcapspeculator
microcapspeculator Aug. 2 at 3:56 PM
$GANX I updated to include latest two research reports plus the recent interview. As mentioned the clinicians have growing confidence of the therapeutic benefits in the phase 1b and all they ever do is work directly with their patients. They never see any blood data but just talk to patients weekly and administer scale tests. Gain Therapeutics(GANX): Latest Analyst Reports(8/1) with Average Target of $8 https://gaintherapeutics.wordpress.com/2025/08/02/gain-therapeuticsganx-latest-analyst-reports8-1-with-average-target-of-8/
0 · Reply
NYC95Greg
NYC95Greg Aug. 1 at 11:42 PM
$GANX - Wow, did you read what I just read from CEO Gene? -Given there is no blood testing now or biomarker conclusions as of yet, why do you think clinicians recommended (and patients agreed) continuing on GT-02287? -It has to be FUNCTIONAL improvement from the drug. Just read between the lines. “As the trial continued, we observed growing comfort among clinicians, which translated into increased enrollment. This is a common dynamic in clinical research—momentum builds as confidence in the therapy grows. In our case, it reflected increasing enthusiasm and optimism about the potential of GT-02287, which was very encouraging.” - Gene Mack https://www.pharmexec.com/view/early-trial-success-promise-gt-02287-parkinson-disease-treatment
1 · Reply
Jwa68
Jwa68 Aug. 1 at 10:01 PM
$GANX It's been a tough couple weeks, none of us are happy with the current stock price. Most believe it highly irrational and some continue to suggest it could change in a heartbeat. Perspective is always important at times like this. Stories about biotech companies just barely holding on by a thread, with its stock in the dumps, and by the next month, they can be valued into the billions May being billions. Tom Brady was the 199th draft pick in 2000... for 6 rounds every team passed on him.... How would you like to be the guy who was responsible for making the 198th pick? I think those selling shares here and those failing to consider capitalizing, are passing the same way, making the same mistake. Have a good weekend. This too shall pass. If GT-02287 works, it is literally priceless...
1 · Reply
Jwa68
Jwa68 Aug. 1 at 9:14 PM
$GANX The more you know...do your due diligence.
1 · Reply
Dave2468999077844
Dave2468999077844 Aug. 1 at 7:25 PM
$GANX Partnership discussions are ongoing with large pharma, biotech, and mid-cap firms.
0 · Reply
Dave2468999077844
Dave2468999077844 Aug. 1 at 7:11 PM
$GANX While treatments like levodopa have certainly benefited patients, there’s still a significant unmet need. Clinicians on the front lines are responsible for their patients’ outcomes and naturally want to see how early participants respond before fully committing. As the trial continued, we observed growing comfort among clinicians, which translated into increased enrollment. This is a common dynamic in clinical research—momentum builds as confidence in the therapy grows. In our case, it reflected increasing enthusiasm and optimism about the potential of GT-02287, which was very encouraging. insert mic drop emoji here.
0 · Reply
microcapspeculator
microcapspeculator Aug. 1 at 7:02 PM
$GANX Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment https://www.pharmexec.com/view/early-trial-success-promise-gt-02287-parkinson-disease-treatment Enrollment for the Phase Ib open-label trial wrapped three months ahead of schedule, driven by growing clinician confidence in the drug’s safety and therapeutic potential.
0 · Reply
Latest News on GANX
Gain Therapeutics Announces Proposed Public Offering

Jul 15, 2025, 4:36 PM EDT - 18 days ago

Gain Therapeutics Announces Proposed Public Offering


Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 28, 2025, 8:30 AM EDT - 4 months ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025


Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Mar 6, 2025, 7:55 AM EST - 5 months ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025


Gain Therapeutics To Present At Biotech Showcase 2025

Dec 11, 2024, 8:30 AM EST - 8 months ago

Gain Therapeutics To Present At Biotech Showcase 2025


Gain Therapeutics, Inc. (GANX) Special Call Transcript

Jul 1, 2024, 10:13 AM EDT - 1 year ago

Gain Therapeutics, Inc. (GANX) Special Call Transcript


Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Jun 27, 2024, 4:08 PM EDT - 1 year ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO


Gain Therapeutics to Present at Public Ventures Discovery Day

Mar 15, 2024, 2:30 PM EDT - 1 year ago

Gain Therapeutics to Present at Public Ventures Discovery Day


Doubling Down On Gain Therapeutics

Dec 22, 2023, 5:56 PM EST - 1 year ago

Doubling Down On Gain Therapeutics


microcapspeculator
microcapspeculator Aug. 3 at 12:43 AM
$GANX Good article. GCase is key. Classification of GBA1 variants and their impact on Parkinson’s disease: an in silico score analysis https://www.nature.com/articles/s41531-025-01060-6 Our PCA-based classification provides a scalable and biologically informed tool for prognostic assessment and future stratification of PD patients with heterozygous GBA1 variants, particularly in the context of clinical trials evaluating targeted therapies, such as chaperone molecules aimed at stabilizing GCase.
1 · Reply
Trade82
Trade82 Aug. 2 at 11:58 PM
$GANX last year 2nd quarter earnings and update was 8/8/24. Hopefully some more updates from company as early as this week.
1 · Reply
Jwa68
Jwa68 Aug. 2 at 5:39 PM
$GANX A little common sense can go a long way. What's the old saying. "right under your nose".
1 · Reply
microcapspeculator
microcapspeculator Aug. 2 at 3:56 PM
$GANX I updated to include latest two research reports plus the recent interview. As mentioned the clinicians have growing confidence of the therapeutic benefits in the phase 1b and all they ever do is work directly with their patients. They never see any blood data but just talk to patients weekly and administer scale tests. Gain Therapeutics(GANX): Latest Analyst Reports(8/1) with Average Target of $8 https://gaintherapeutics.wordpress.com/2025/08/02/gain-therapeuticsganx-latest-analyst-reports8-1-with-average-target-of-8/
0 · Reply
NYC95Greg
NYC95Greg Aug. 1 at 11:42 PM
$GANX - Wow, did you read what I just read from CEO Gene? -Given there is no blood testing now or biomarker conclusions as of yet, why do you think clinicians recommended (and patients agreed) continuing on GT-02287? -It has to be FUNCTIONAL improvement from the drug. Just read between the lines. “As the trial continued, we observed growing comfort among clinicians, which translated into increased enrollment. This is a common dynamic in clinical research—momentum builds as confidence in the therapy grows. In our case, it reflected increasing enthusiasm and optimism about the potential of GT-02287, which was very encouraging.” - Gene Mack https://www.pharmexec.com/view/early-trial-success-promise-gt-02287-parkinson-disease-treatment
1 · Reply
Jwa68
Jwa68 Aug. 1 at 10:01 PM
$GANX It's been a tough couple weeks, none of us are happy with the current stock price. Most believe it highly irrational and some continue to suggest it could change in a heartbeat. Perspective is always important at times like this. Stories about biotech companies just barely holding on by a thread, with its stock in the dumps, and by the next month, they can be valued into the billions May being billions. Tom Brady was the 199th draft pick in 2000... for 6 rounds every team passed on him.... How would you like to be the guy who was responsible for making the 198th pick? I think those selling shares here and those failing to consider capitalizing, are passing the same way, making the same mistake. Have a good weekend. This too shall pass. If GT-02287 works, it is literally priceless...
1 · Reply
Jwa68
Jwa68 Aug. 1 at 9:14 PM
$GANX The more you know...do your due diligence.
1 · Reply
Dave2468999077844
Dave2468999077844 Aug. 1 at 7:25 PM
$GANX Partnership discussions are ongoing with large pharma, biotech, and mid-cap firms.
0 · Reply
Dave2468999077844
Dave2468999077844 Aug. 1 at 7:11 PM
$GANX While treatments like levodopa have certainly benefited patients, there’s still a significant unmet need. Clinicians on the front lines are responsible for their patients’ outcomes and naturally want to see how early participants respond before fully committing. As the trial continued, we observed growing comfort among clinicians, which translated into increased enrollment. This is a common dynamic in clinical research—momentum builds as confidence in the therapy grows. In our case, it reflected increasing enthusiasm and optimism about the potential of GT-02287, which was very encouraging. insert mic drop emoji here.
0 · Reply
microcapspeculator
microcapspeculator Aug. 1 at 7:02 PM
$GANX Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment https://www.pharmexec.com/view/early-trial-success-promise-gt-02287-parkinson-disease-treatment Enrollment for the Phase Ib open-label trial wrapped three months ahead of schedule, driven by growing clinician confidence in the drug’s safety and therapeutic potential.
0 · Reply
Gandalf01
Gandalf01 Aug. 1 at 5:30 PM
$GANX anyone looking at $CGTX today? It's ripping in a down market.
2 · Reply
Jwa68
Jwa68 Aug. 1 at 1:04 PM
$GANX Penicillin, Aspirin, Insulin etc., some of the most important drug discoveries that changed medicine. The first disease modifying drug for Parkinson's disease alone would cause it to be added to the list. PD is an exploding epidemic and there are no viable drugs to address it. Large pharma will want their name all over any drug that addresses it for their social capital alone. Is GT-02287 possibly that drug? While the share price may cause one to wonder, that can change in a split second. The question will be answered in a short matter of months. Historically GT-02287 has surprised at every turn...I expect it could again. Some very educated analysts think it's a possible block buster and unicorn. They said on the BTIG call they see $2.5B in annual sales based on just 25% market share. Put a conservative multiple on that with 45M shares fully diluted. You will need a calculator... Take a picture of today's market value for posterity. Do your own dd.
1 · Reply
john_Ennis
john_Ennis Aug. 1 at 12:28 PM
$GANX does anyone else have a position in AKBA ? They have oral drug for anemia in kidney patients. Q2 revenue next week is expected to be amazing. Just wondering.
0 · Reply
ROHCPA
ROHCPA Aug. 1 at 8:12 AM
$GANX In regards to Trader82 post the other day, I emailed Apaar and asked him, "I thought the trial was fully enrolled" What is this? His response below The trial listed below is a recently completed bioequivalence study. As indicated by the public title “A clinical study to compare the safety and tolerability of two formulations of a new drug in Healthy Participants for Parkinson's disease”, we evaluated the bioavailability of the current formulation of GT-02287 against a new formulation of GT-02287.
2 · Reply
microcapspeculator
microcapspeculator Aug. 1 at 12:14 AM
$GANX This is an article from another Allosteric discovery company that is targeting cancer. Allosterics still in the early stages. https://www.hotspotthera.com/a-complex-solution-to-a-complex-problem-attacking-krasg12x-colorectal-cancer-through-the-cbm-signalosome/
1 · Reply
JP73
JP73 Jul. 31 at 11:18 PM
$GANX One pumper has blocked me already in minutes (Jwa68 ); apparently his panties got in bunch when a solid observation came to its eyes. If someone is that soft, should they really be in the market?
5 · Reply
arcuy
arcuy Jul. 31 at 11:02 PM
$GANX @Jwa68 You still here? $ATNF?
0 · Reply
JP73
JP73 Jul. 31 at 10:53 PM
$GANX Horrible chart and fundamentally has not shown ****. Pumpers stop pumping.
1 · Reply
Naf3332
Naf3332 Jul. 31 at 9:57 PM
$GANX unfortunately down 15% in a few days isn’t dull. Lol. More like painful. I keep buying but I’m crazy.
3 · Reply
john_Ennis
john_Ennis Jul. 31 at 6:58 PM
$GANX will it be this dull till October ?
0 · Reply
PaulWalter
PaulWalter Jul. 31 at 1:43 PM
$GANX added
0 · Reply
Jwa68
Jwa68 Jul. 31 at 12:22 PM
$GANX RESOLUTE.
0 · Reply